US says 'no concerns' with vaccines eyed in Japan deaths

Mar 07, 2011

US health officials said Monday they have had no reports that arouse new safety concerns over two children's vaccines that have been suspended in Japan following the deaths of four babies.

Researchers at the (FDA) and (CDC) "have not detected new safety concerns or unusual reporting patterns" among children given the vaccines against bacteria that can cause meningitis and pneumonia, FDA spokeswoman Shelly Burgess said.

Japanese health authorities ordered doctors to stop using the two vaccines -- Prevenar, made by US-based Pfizer, and ActHIB, made by the Sanofi Pasteur wing of Paris-headquartered Sanofi-Aventis -- following the deaths of four infants who were given the shots alone or in combination with others drugs.

The infants, aged from around six months to under two years old, all died between March 2 and 4, Japanese officials said.

In addition to the four cases, Japan's health ministry said another infant died in November after receiving his second shot of the ActHIB , a Japanese health ministry official said.

The FDA and CDC are aware of the babies' deaths and of the suspension of the two vaccines in , a statement sent by Burgess to AFP said.

US health agencies were continuing to monitor the safety of all vaccines, including those against the haemophilus influenzae type b (Hib) bacteria and streptococcus pneumoniae targeted by ActHIB and Prevenar, the statement said.

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Kids' Swine flu shots recalled; not strong enough

Dec 15, 2009

(AP) -- Hundreds of thousands of swine flu shots for children have been recalled because tests indicate the vaccine doses lost some strength, government health officials said Tuesday.

WHO: nearly 5,000 swine flu deaths worldwide

Oct 23, 2009

(AP) -- Nearly 5,000 people have reportedly died from swine flu since it emerged this year and developed into a global epidemic, the World Health Organization said Friday.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

9 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Caliban
not rated yet Mar 07, 2011
What is the sample size? Are 5 fatalities of any statistical relevance? Why the sketchy info -almost zero context.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.